Steven G Self
Overview
Explore the profile of Steven G Self including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
4016
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Asbach B, Kibler K, Kostler J, Perdiguero B, Yates N, Stanfield-Oakley S, et al.
J Virol
. 2018 Nov;
93(3).
PMID: 30429343
The use of heterologous immunization regimens and improved vector systems has led to increases in immunogenicity of HIV-1 vaccine candidates in nonhuman primates. In order to resolve interrelations between different...
2.
Nemes E, Geldenhuys H, Rozot V, Rutkowski K, Ratangee F, Bilek N, et al.
N Engl J Med
. 2018 Jul;
379(2):138-149.
PMID: 29996082
Background: Recent Mycobacterium tuberculosis infection confers a predisposition to the development of tuberculosis disease, the leading killer among global infectious diseases. H4:IC31, a candidate subunit vaccine, has shown protection against...
3.
Moodie Z, Juraska M, Huang Y, Zhuang Y, Fong Y, Carpp L, et al.
J Infect Dis
. 2017 Dec;
217(5):742-753.
PMID: 29194547
Background: In the CYD14 and CYD15 Phase 3 trials of the CYD-TDV dengue vaccine, estimated vaccine efficacy (VE) against symptomatic, virologically confirmed dengue (VCD) occurring between months 13 and 25...
4.
Garcia-Arriaza J, Perdiguero B, Heeney J, Seaman M, Montefiori D, Yates N, et al.
J Virol
. 2017 Feb;
91(9).
PMID: 28179536
The nonreplicating attenuated poxvirus vector NYVAC expressing clade C(CN54) HIV-1 Env(gp120) and Gag-Pol-Nef antigens (NYVAC-C) showed limited immunogenicity in phase I clinical trials. To enhance the capacity of the NYVAC...
5.
Asbach B, Kliche A, Kostler J, Perdiguero B, Esteban M, Jacobs B, et al.
J Virol
. 2016 Feb;
90(8):4133-4149.
PMID: 26865719
Unlabelled: In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine field seek to substantiate and extend the results by evaluating other poxvirus...
6.
Gantt S, Yao L, Kollmann T, Casper C, Zhang J, Self S
J Pediatric Infect Dis Soc
. 2015 Dec;
2(2):162-70.
PMID: 26619463
Epidemics of enterovirus serotype 71 (EV71) infection in Asia appear to be increasing in size and severity, and there is increasing concern for pandemic spread. Efforts are underway to develop...
7.
Walsh S, Moodie Z, Fiore-Gartland A, Morgan C, Wilck M, Hammer S, et al.
J Infect Dis
. 2015 Oct;
213(4):541-50.
PMID: 26475930
Background: Increasing the breadth of human immunodeficiency virus type 1 (HIV-1) vaccine-elicited immune responses or targeting conserved regions may improve coverage of circulating strains. HIV Vaccine Trials Network 083 tested...
8.
Li X, Paulson T, Galipeau P, Sanchez C, Liu K, Kuhner M, et al.
Cancer Prev Res (Phila)
. 2015 Jul;
8(9):845-56.
PMID: 26130253
Cancers detected at a late stage are often refractory to treatments and ultimately lethal. Early detection can significantly increase survival probability, but attempts to reduce mortality by early detection have...
9.
Chen X, Chen J, Zhang L, Li J, Yao L, Self S, et al.
Chemosphere
. 2014 Dec;
118:1-4.
PMID: 25433396
Several studies have suggested that maternal exposure to Polychlorinated dibenzo-p-dioxins (PCDDs), poly-chlorinated dibenzofurans (PCDFs) and dioxin-like polychlorinated biphenyls (PCBs) may affect foetal growth and infant development. The aim of our...
10.
Hawn T, Day T, Scriba T, Hatherill M, Hanekom W, Evans T, et al.
Microbiol Mol Biol Rev
. 2014 Nov;
78(4):650-71.
PMID: 25428938
Tuberculosis (TB) is a leading cause of death worldwide despite the availability of effective chemotherapy for over 60 years. Although Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccination protects against active TB...